Trial Profile
A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex-matched subjects
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Pharmacodynamics
- 20 Jul 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 07 Oct 2011 New trial record